Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non - small-cell lung cancer

Journal of Clinical Oncology

Volumn 27, Issue 34, 2009, Pages 5808-5815

  Reynolds, Craig ^a   Obasaju, Coleman ^a   Schell, Michael J ^a   Li, Xueli ^a   Zheng, Zhong ^a   Boulware, David ^a   Caton, John R ^a   DeMarco, Linda C ^a   O'Rourke, Mark A ^a   Wright, Gail Shaw ^a   Boehm, Kristi A ^a   Asmar, Lina ^a   Bromund, Jane ^a   Peng, Guangbin ^a   Monberg, Matthew J ^a   Bepler, Gerold ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; PROTEIN RRM1; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DNA BINDING PROTEIN; DRUG DERIVATIVE; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; RRM1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; DNA REPAIR; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 73349109815     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.9766     Document Type: Article

References (27)

1. NCCN: Non-Small Cell Lung Cancer: NCCN Clinical Practice Guidelines in Oncology V. 2.2008, 2008. www.nccn.org
2. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non - small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
3. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
4. Fossella F, Pereira JR, von Pawel J, et al: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 21:1-9, 2003
5. Lilenbaum R, Herndon JE, List MA, et al: Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol 23:190-196, 2005
6. Langer C, Li S, Schiller JH, et al: Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 25:418-423, 2007
7. Lord RVN, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286-2291, 2002
8. Rosell R, Danenberg KD, Alberola V, et al: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10:1318-1325, 2004
9. Bepler G, Kusmartseva I, Sharma S, et al: RRM1-modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small cell lung cancer. J Clin Oncol 24:4731-4737, 2006
10. Ceppi P, Volante M, Novello S, et al: ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17:1818-1825, 2006
11. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991, 2006
12. Volker M, Mone MJ, Karmakar P, et al: Sequential assembly of the nucleotide excision repair factors in vivo. Molec Cell 8:213-224, 2001
13. Stubbe J: Ribonucleotide reductases in the twenty-first century. Proc Natl Acad Sci U S A 95:2723-2724, 1998
14. Chen G, Gharib TG, Huang CC, et al: Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 1:304-313, 2002
15. Zheng Z, Chen T, Li X, et al: The DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800-808, 2007
16. American Joint Committee on Cancer: Staging Handbook (ed 6). New York, NY, Springer-Verlag, 2002
17. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
19. Camp RL, Chung GG, Rimm DL: Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8:1323-1327, 2002
20. Miller R, Siegmund D: Maximally selected chisquare statistics. Biometrics 38:1011-1016, 1982
21. Neubauer MA, Reynolds CH, Joppert MG, et al: Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2. Clin Lung Cancer 6:245-249, 2005
22. Perrone F, Di Maio M, Gallo C, et al: Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES). J Clin Oncol 22:5018-5020, 2004
23. Kosmidis PA, Dimopoulos MA, Syrigos K, et al: Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: A prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol 2:135-140, 2007
24. Nakahira S, Nakamori S, Tsujie M, et al: Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 120:1355-1363, 2007
25. Dabholkar M, Vionnet J, Bostick-Bruton F, et al: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94:703-708, 1994
26. Shirota Y, Stoehlmacher J, Brabender J, et al: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298-4304, 2001
27. Huang P, Chubb S, Hertel LW, et al: Action of 2′,2′- difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117, 1991